Summer Sale
50% off Premium Yearly
Opinions Julien Nono-Womdim
Harrow Inc.HROWTOP PICKSep 15, 2025
Julien Nono-WomdimStock price when the opinion was issued
As of Jun 15, 2026. Market Open.
You might be interested:
A volatile stock. A recent drug launch has been good, though a little slower than expected. There's a lot of competition, but he expects growth. They so well buying companies and striking relationships with doctors.
Julien Nono-WomdimHROW had a iss on earnings of $0.22 vs $0.26 expected and revenue was a bit shy at $71.6 vs $73.7 expected. There was a bit of a disruption in one of their businesses leading to the miss on the quarter but the branded business is seeing momentum and good volumes showing robust demand looking forward. The company also recently closed the MELT acquisiton which should be a tailwind in the next year. The current quarter itself was on the weaker side but markets like the outlook here.
Unlock Premium - Try 5i Free
HROW had a iss on earnings of $0.22 vs $0.26 expected and revenue was a bit shy at $71.6 vs $73.7 expected. There was a bit of a disruption in one of their businesses leading to the miss on the quarter but the branded business is seeing momentum and good volumes showing robust demand looking forward. The company also recently closed the MELT acquisiton which should be a tailwind in the next year. The current quarter itself was on the weaker side but markets like the outlook here.
Unlock Premium - Try 5i Free
HROW had a iss on earnings of $0.22 vs $0.26 expected and revenue was a bit shy at $71.6 vs $73.7 expected. There was a bit of a disruption in one of their businesses leading to the miss on the quarter but the branded business is seeing momentum and good volumes showing robust demand looking forward. The company also recently closed the MELT acquisiton which should be a tailwind in the next year. The current quarter itself was on the weaker side but markets like the outlook here.
Unlock Premium - Try 5i Free
It is in the eye care business and focuses on ophthalmology and biotech. One question is how easily can they get drugs to patients. Their first interesting drug is for dry eyes and the second is an anesthetic for surgeries, especially cataract surgery. This one is stable and consistent from patient to patient. Other anesthetics vary in their length of time they are effective from patient to patient. Has stable cash flows from its compounding business and accelerating growth from key products. Could get from under $300 million in revenue today to $1 billion in revenue in the next four years as well as tripling margins. Buy 8 Hold 0 Sell 0
(Analysts’ price target is $59.83)